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ABSTRACT
Aim: Three weeks paclitaxel and carboplatin has been considered the standard 
of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will 
further improve the clinical outcomes or not is still unclear. We conducted a meta-
analysis to compare the two regimens.
Method: Articles were selected with a systematic approach, using PubMed 
databases. Trials concerning comparison between carboplatin plus weekly paclitaxel 
(dose-dense regimen) and carboplatin plus paclitaxel every 3 weeks were considered. 
Outcomes included overall survival (OS), progression free survival (PFS) and severe 
acute toxicity.
Results: Dose-dense regimen was associated with significant improvement of PFS 
compared with standard schedule, with HR of 0.73 (95% CI 0.61-0.88, p = 0.001). 
There was no difference in OS between treatment regimens (HR 0.95, 95% CI 0.77-
1.16, p=0.06), as well as in term of severe acute toxicity. 
Conclusion: Dose-dense regimen is superior to standard schedule in terms of 
PFS. Further studies are necessary to firmly confirm this evidence in advanced OC 
treatment.
INTRODUCTION
Paclitaxel and carboplatin regimen is considered the 
standard of care for patients with newly diagnosed ovarian 
cancer (OC) [1]. It is recommended an intravenous 
infusion of 3-hour paclitaxel 175 mg/m2 and carboplatin 
at an area under the curve (AUC) of 6 mg/ml/min repeated 
every 3 weeks for six cycles. In attempt to improve clinical 
outcomes, based on the efficacy demonstrated in breast 
cancer [2], new schedules have been tested, including 
dose-dense regimen. Generally it consisted of weekly 
paclitaxel plus carboplatin given every 3 weeks. Doses 
depend on trials and range from paclitaxel 60 mg/m2 to 
90 mg/m2 and carboplatin AUC 2 mg/ml/min to AUC 6 
mg/ml/min [3-6]. However, at present, there is no data 
indicating which regimen is superior. 
The main purpose of this meta-analysis was 
to compare the efficacy of weekly versus 3 weeks 




The meta-analysis included randomized phase III 
trials, only. Figure 1 shows the study selection process. 
The literature search identified a total of 29 
potentially relevant articles. Articles were excluded 
because the subject matter was not related to the study (n 
= 9), or the trial was not randomized phase III (n = 3), or 
it was a review (n = 7), or the article was not published 
in English (n = 1) or they were duplicate articles (n = 5).
                                  Review
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To avoid bias and reduce heterogeneity, van der 
Burg trial was excluded, due to double randomization 
performed in the study design [6]. At the end of the review 
process, 3 trials were eligible (2133 patients) comparing 
carboplatin plus weekly paclitaxel versus carboplatin plus 
paclitaxel every 3 weeks [3-5]. 
In one trial (Gynecologic Oncology Group (GOG) 
0262, [5]) patients in either group could opt to receive 
bevacizumab. For survival analysis, update published 
follow-up data were considered for one trial [11]. Main 
characteristics of the trials are shown in Table 1. 
Progression free survival
Overall, PFS after weekly schedule was significantly 
better than PFS after 3-weekly regimen (HR 0.87, 95% CI 
0.76-0.99, p = 0.04; I2 30%; Figure 2).
Considering that MITO-7 trial [4] had dissimilar 
carboplatin administration schedule (AUC 2 mg/mL 
per min versus AUC 6 mg/mL per min), we performed 
a subgroup analysis for drug dose. Moreover, since the 
GOG 0262 study design [5] provided bevacizumab 
to each patient who chose to receive it, only data from 
the subgroup of patients who elected to not receive 
bevacizumab were included. Thus, the following sub-
group analysis concerned data from GOG 0262 study 
(without bevacizumab) and JGOG 3016 study, including 
a total of 743 patients. The benefit of weekly schedule on 
PFS was statistically significant compared with 3-weekly 
regimen (HR 0.73, 95% CI 0.61-0.88, p = 0.001; I2 0%; 
Figure 3)
Overall survival
There was no statistically significant beneficial 
effect for OS comparing weekly versus 3-weekly schedule 
(HR 0.95, 95% CI 0.77-1.16, p = 0.06; I2 64%; Figure 
4). The effect of both schedules without bevacizumab 
on OS was not assessable, because GOG-0262 data on 
OS that included only patients who opted not to receive 
bevacizumab were not available [5]. 
Toxicity
Overall the incidence of severe acute toxicity was 
similar between groups. Details are shown in Figure 
5. When carboplatin AUC 6 mg/mL per min data were 
analyzed, the rates of anemia G3-4 (HR 2.95, 95% CI 
2.32-3.77, p = 0.00001; I2 0%), thrombocytopenia G3-4 
(HR 1.28, 95% CI 1.00-1.64, p = 0.05; I2 0%) and diarrhea 
G3-4 (HR 1.78, 95%CI 1.00-3.18, p = 0.05; I2 0%) were 
significantly higher in weekly regimen.
DISCUSSION
Our meta-analysis demonstrates that, although 
there was no difference in OS and severe acute toxicity, 
carboplatin plus weekly paclitaxel administration 
significantly improves PFS in frontline treatment of 
advanced OC (HR 0.87, 95% CI 0.76-0.99). In particular, 
we found a clear advantage when chemotherapy was 
administered as carboplatin AUC 6 mg/mL per min 
every 3 weeks and weekly paclitaxel 80 mg/m2 (HR 0.73, 
95% CI 0.61-0.88). This is considered the “standard” 
Table 1: Trials’ characteristics
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experimental regimen and is named dose-dense as in 
literature. 
This meta-analysis was initially performed to clarify 
whether dose-dense chemotherapy might enhance the 
effect of chemotherapy in the first line treatment of OC, 
with improved toxicity profile, as it had been shown in 
other cancers [8]. 
Several randomized trials addressing this question 
have been conducted in OC but study design and dose 
administration were partly heterogeneous and, accordingly, 
results were controversial. Thus, we tried to focus on the 
dose-dense schedule which has obtained the greatest 
improvement - carboplatin AUC 6 mg/mL per min every 
3 weeks and weekly paclitaxel 80 mg/m2 -. This dose-
dense schedule was beforehand investigated by Katsumata 
et al [7]. They found an impressive longer median PFS 
(28.2 months versus 17.5 months; p = 0·0037) as well as 
median OS (100.5 months versus 62.2 months; 0.039) 
in those patients who received dose-dense experimental 
combination compared with conventional chemotherapy. 
Nonetheless, these data were claimed to be limited to 
the Japanese population which has been shown to have a 
significantly better survival compared with non-Hispanic 
white patients [9-10]. With this regard, duPont et al [9] 
enrolled patients from South Korea and Japan in the GOG 
218 trial and found a significantly longer OS in Asian 
patients when adjusted for age, stage, residual disease, 
performance status, and histology. These data need to be 
confirmed in prospective trial, aimed to explore biological 
differences, environmental factors, socioeconomic factors, 
and response to treatment. Nonetheless it should be 
underlined that when looking at those patients from the 
GOG 0262 trial who did not received bevacizumab, data 
about PFS advantage are extraordinary similar in terms of 
PFS improvement (HR 0.62, 95% CI 0.40 - 0.95) [5], thus 
justifying the advantage we found in our meta-analysis. 
Therefore, we can assume that in terms of absolute months 
of OS and PFS, Asiatic population might have a definitive 
and ethnic-specific advantage, but the reason for the PFS 
increment across the two different populations - Asiatic in 
the JGOG 3016 and non-Hispanic white patients in GOG 
0262 - has to be searched not in the ethnicity but in the 
schedule of treatment received. 
We did not found any survival advantage in 
the OS analysis. Nonetheless, as for toxicity, OS data 
where not homogenous, since results from the GOG 
Figure 1: PRISMA flow diagram.
Figure 2: Progression free survival of overall cohort.
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0262 trial where limited to aggregate analysis, without 
splitting OS data between those who and who did not 
received bevacizumab. It might be supposed that the 
anti-angiogenic properties of bevacizumab might have 
overlap the anti-angiogenic activity of weekly paclitaxel 
as well as tumor perfusion and drug delivery, and this 
might have confused the peculiar efficacy of dose dense 
administration. Considering that the OS results approached 
statistical significance (p = 0.06), one may speculate 
that the present meta-analysis might be underpowered 
to identify a small, but clinically important OS benefit. 
Therefore, we acknowledge that the present OS results 
may not be seen as definitive due to the small number of 
trials presently available. Data from ICON8 and ICON8b 
trials are currently ongoing and addressing these questions 
[11].
Regardless, it should also be underlined that in each 
trial included in our analysis, the PFS was the primary end 
point of the study. The debate on the role of PFS as primary 
endpoint in OC clinical trials has been longley discussed 
and in the last years it has become to be considered as a 
surrogate endpoint of OS. The advantages of this endpoint 
are an earlier and more sensitive assessment of antitumor 
efficacy, a lower likelihood of influence by competing 
risks (especially in elderly subjects), and a lesser chance 
of confounding because of treatments received after 
progression. 
Unfortunately we were unable to present toxicity 
data limited to patients who received dose-dense 
paclitaxel, without other drugs. In fact, it was not possible 
to distinguish between patients receiving bevacizumab 
form those only receiving doublet combination, in the 
GOG 0262 trial [5]. Interestingly, when looking to 
cumulative toxicity data, we noticed an increase of anemia, 
thrombocytopenia and diarrhea in those who received 
dose-dense schedule. Whether or not these adverse events 
have to be more related with bevacizumab is not possible 
to define; nevertheless our toxicity results were consistent 
with previous findings [8], even if partially in contrast 
with the initial expectation of lower toxicity rates with a 
dose-dense schedule. It is reasonable to hypothesize that 
the greater number of infusions and longer duration of 
paclitaxel exposure with a dose-dense regimen enhance 
intratumoral drug perfusion and inhibit angiogenesis, 
achieving a mechanism of efficacy and a toxicity profile 
comparable to that of bevacizumab. Furthermore, it 
appears that quality of life, which has been investigated 
in these trials [4-5, 12], is not significantly impaired by 
dose-dense administration, thus suggesting that even if 
more toxic, this kind of schedule is overall tolerable and 
manageable. 
Our meta-analysis has some limitations. As stated 
above, none of the eligible trials was designed to measure 
the OS as primary outcome. Furthermore, our meta-
analysis was based on data from trials that have published 
results in the literature. The use of updated individual 
patient data might further enhance the accuracy and 
reduced the uncertainty of the observed estimates [13-
14]. However, we made an effort to include all additional 
information that we could obtain and definitions for the 
analyzed outcomes were largely consistent across studies. 
Another limitation of this meta-analysis is that there was 
heterogeneity in the design, modes of treatment used in 
each study. Due to the notable differences in the study 
design and regimens used it is difficult to reach firm 
conclusions. Finally we should consider that the cohort of 
patients receving dose-dense schedule is rather small and 
larger population would be helpful to confirm our results. 
Allowing for these cautions, our meta-analysis 
provides evidence that dose-dense regime results in 
Figure 3: Progression free survival: Subgroup analysis in trials comparing weekly paclitaxel plus carboplatin (AUC 6 
mg/mL per min) with paclitaxel given every 3 weeks plus carboplatin (AUC 6 mg/mL per min).
Figure 4: Overall survival of overall cohort.
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Figure 5: Severe acute toxicity.
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consistent PFS advantage. We believe that these results 
provide further insight into the argument concerning 
the optimal dose and schedule of front line therapy in 
advanced OC. More randomized studies with better drug 
use and patient selection are needed; next studies should 
also clarify which is the role of bevacizuamb in the 
dose-dense schedule. If our findings will be confirmed, 
dose-dense schedule might become a valid approach for 
advanced OC treatment. 
Dose-dense regimen, based on carboplatin AUC 6 
mg/mL per min every 3 weeks and weekly paclitaxel 80 
mg/m2 seems to guarantee an important PFS benefit in 
patients with advanced OC. Its precise superiority in the 
management of OC remains to be determined.
MATERIALS AND METHODS
Data extraction and trials selection
The preferred reporting items for systematic reviews 
and meta-analyses (PRISMA) guidelines were followed 
to perform search strategy and selection processes. The 
meta-analysis included trials without any restrictions 
on publication date. The last search was carried out on 
April 2016. Systematic literature electronic search was 
conducted in Pubmed, Medline and Scopus databases. 
The search term used were “randomized”, “dose-dense”, 
“paclitaxel”, “carboplatin”, “3 weeks”, “weekly” and 
“ovarian cancer” in the title. These key words were 
variably combined: 1. “randomized paclitaxel carboplatin 
weekly 3 weeks ovarian cancer”; 2. “randomized dose-
dense paclitaxel carboplatin weekly ovarian cancer”. 
The inclusion criteria included randomized controlled 
trials that compared carboplatin plus weekly paclitaxel 
with standard schedule of carboplatin plus paclitaxel 
every 3 weeks in OC. Randomized clinical trials, written 
in English, were included, without any restrictions 
on publication date. We excluded trials meeting the 
following criteria: non-randomized, single-arm phase II 
trial or adequate statistical analysis information missing. 
Reference lists of previously published reviews and meta-
analysis were explored. Review articles, case reports, 
commentaries, and letters were not included, and meeting 
abstracts were not considered because of the insufficient 
data provided by the authors. 
Two independent reviewers (CM and FDF) selected 
the identified studies based on the title and abstract. If the 
topic of the study could not be ascertained from its title or 
abstract, the full-text version was retrieved for evaluation. 
Disagreement was resolved by discussion or consensus or 
with a third party (LM). Trials were eligible if participants 
were newly diagnosed, with histologically or cytologically 
proven epithelial ovarian, fallopian tube, or primary 
peritoneal cancer at study entry. In closer evaluation of 
potentially eligible articles, when two articles appeared 
to report results with overlapping data, only the data 
representing the most recent publication were included in 
the meta-analysis. 
The extracted data for each trial were recorded 
into standardized database according to the following 
parameters: first author’s surname, year of publication, 
trial acronym, sample size of weekly and 3 weeks group, 
chemotherapy regimen, drug and dosage. 
Endpoints
The primary end points were progression free 
survival (PFS) and overall survival (OS). Severe acute 
toxicity was secondary end point. 
The definition of both PFS and OS was similar 
across trials. PFS was defined as the time from the date 
of randomization to last follow-up, death or disease 
progression. OS was defined as the time from the date of 
randomization to last follow-up or death. The hazard ratio 
(HR) and the number of events (death and progression), 
when available, were derived from each study. At least 
one of these two outcomes should have been assessed and 
reported in the trial to be included in the present analysis. 
Among trials reporting the results of different therapeutic 
approaches, when possible, we selected and included 
in a subgroup analysis only the groups of patients who 
underwent to similar strategies. 
We also planned to analyze severe acute toxicity. 
The following adverse effects grade ≥ 3 were recorded: 
neutropenia, thrombocytopenia, anemia, febrile 
neutropenia, vomiting, diarrhea, fatigue and neuropathy.
Statistical analysis
Statistical analysis was performed using Review 
Manager 5.0 (http://www.cochrane.org). The pooled HR 
was calculated using a random-effects model. Forest 
plots were used for graphical representation of each study 
and pooled analysis. The size of each box represents the 
weight that the corresponding study exerts in the meta-
analysis; confidence intervals (CIs) for each study are 
displayed as a horizontal line through the box. The pooled 
HR is symbolized by a solid diamond at the bottom of 
the forest plot, and the width of the square represents 
the 95 % CI of the HR. HR, variance, 95 % CI, log [risk 
ratio] and standard error for each study were extracted or 
calculated, based on the published studies, according to 
the methods described by Tierney et al. in 2007 [15]. A 
significant two-way p value for comparison was defined 
as p < 0.05. Statistical heterogeneity among studies was 
examined using both the Cochrane Q statistic (significant 
at p < 0.1) and the I2 value (significant heterogeneity if > 
50 %) [16]. Publication bias was examined using analyses 
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